database / melanocortin
Setmelanotide
also known as Imcivree
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 11993702. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
Cyclic octapeptide with non-standard residues; approved for rare genetic obesity conditions.
Molecular data
| molecular formula | C49H68N18O9S2 |
|---|---|
| molecular weight | 1117.3 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 11993702 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
MC4R agonist.
Reported targets: MC4R
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| weight outcomes in trials | Bardet-Biedl Syndrome StatPearls Publishing, Treasure Island (FL) 2026 |
| hunger scores in trials | Safety and effectiveness of setmelanotide in young patients with severe obes… Journal of endocrinological investigation 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT06772597 | A Study of Setmelanotide in Patients With Prader-Willi Syndrome | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01867437 | Effects of RM-493 on Energy Expenditure in Obese Individuals | COMPLETED | PHASE1 |
| NCT03651765 | Long Term Extension Trial of Setmelanotide | COMPLETED | PHASE2, PHASE3 |
| NCT07674290 | Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity | RECRUITING | PHASE4 |
| NCT02311673 | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participant | COMPLETED | PHASE2 |
Literature (8)
Bardet-Biedl Syndrome — StatPearls Publishing, Treasure Island (FL) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42475468
Safety and effectiveness of setmelanotide in young patients with severe obesity due to craniopharyngioma: a real world monocentric experience — Journal of endocrinological investigation 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42329358 · DOI 10.1007/s40618-026-02950-z
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity — The New England journal of medicine 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42418774 · DOI 10.1056/nejmoa2512275
Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency — Obesity (Silver Spring, Md.) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42068058 · DOI 10.1002/oby.70213
Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide — The Journal of clinical endocrinology and metabolism 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42538728 · DOI 10.1210/clinem/dgag293
Case Report: Effect of setmelanotide treatment in a young patient with acquired hypothalamic obesity following <i>Escherichia coli</i> sepsis and meningoencephalitis with brain abscess — Frontiers in endocrinology 2026
Acquired hypothalamic obesity (aHO) is a rare and severe condition caused by injury to hypothalamic centers regulating appetite, energy balance, and neuroendocrine function. It is characterized by rapid weight gain, hyperphagia, and significant metabolic complications, and current treatment options remain limited. We report the case of a 22-month-old child who developed severe acquired hypothalamic obesity following neonatal Escherichia coli sepsis complicated by meningoencephalitis and brain abscess. Treatment with the melanocortin-4 receptor agonist setmelanotide was initiated at [dose redacted] daily and gradually titrated to 1.5 mg. Over 13 months of treatment, the patient experienced stabilization and a subsequent reduction in body weight, improvement in liver enzymes and lipid profile, increased motor activity, and marked improvements in interaction and quality of life. The most pronounced…
open access ↗ · PMID 42339090 · DOI 10.3389/fendo.2026.1796227
Setmelanotide in Bardet-Biedl Syndrome: A Case Report — Pediatric dermatology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41994885 · DOI 10.1111/pde.70186
Setmelanotide (Imcivree): CADTH Reimbursement Review: Therapeutic area: Bardet-Biedl syndrome — Canadian Agency for Drugs and Technologies in Health, Ottawa (ON) 2023
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
open access ↗ · PMID 38301066
Related
Melanotan II
melanocortin · 8 citations
Afamelanotide
melanocortin · 8 citations
Bremelanotide
melanocortin · 8 citations
α-MSH
melanocortin · 8 citations